Description

Simple

A medication used to relax muscles or as an anesthesia to stop pain during surgeries.

Clinical

A nondepolarizing neuromuscular blocking agent used to relax muscles or as an adjunct in general anesthesia during surgical procedures.

Overview

Monoquaternary homolog of pancuronium. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.

Pharmacology

Indication

Vecuronium is a muscle relaxing agent and is used as an adjunct in general anesthesia.

Pharmacodynamic

The principal pharmacologic effects demonstrated by vecuronium revolve around its competitive binding of cholinergic receptors located at motor end plates. This competitive binding results in muscle relaxant effects that are typically employed as an adjunct to general anesthesia.

Mechanism of action

Vecuronium is a bisquaternary nitrogen compound that acts by competitively binding to nicotinic cholinergic receptors. The binding of vecuronium decreases the opportunity for acetylcholine to bind to the nicotinic receptor at the postjunctional membrane of the myoneural junction. As a result, depola... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

51–80 minutes

Route of elimination

Fecal (40-75%) and renal (30% as unchanged drug and metabolites)

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Vecuronium
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
1,10-Phenanthroline
1,10-Phenanthroline may decrease the neuromuscular blocking activities of Vecuronium.
2,5-Dimethoxy-4-ethylthioamphetamine
The risk or severity of adverse effects can be increased when Vecuronium is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of adverse effects can be increased when Vecuronium is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-Methoxyamphetamine
The risk or severity of adverse effects can be increased when Vecuronium is combined with 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamine
The risk or severity of adverse effects can be increased when Vecuronium is combined with 5-methoxy-N,N-dimethyltryptamine.
7-Nitroindazole
The risk or severity of adverse effects can be increased when Vecuronium is combined with 7-Nitroindazole.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
The risk or severity of adverse effects can be increased when Vecuronium is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Acepromazine
The risk or severity of adverse effects can be increased when Vecuronium is combined with Acepromazine.
Aceprometazine
The risk or severity of adverse effects can be increased when Vecuronium is combined with Aceprometazine.
Acetazolamide
The risk or severity of adverse effects can be increased when Acetazolamide is combined with Vecuronium.
Acetophenazine
The risk or severity of adverse effects can be increased when Acetophenazine is combined with Vecuronium.
Acetyldigitoxin
The risk or severity of Cardiac Arrhythmia can be increased when Vecuronium is combined with Acetyldigitoxin.
Acetyldigoxin
The risk or severity of Cardiac Arrhythmia can be increased when Vecuronium is combined with Acetyldigoxin.
Acetylglycinamide chloral hydrate
The risk or severity of adverse effects can be increased when Vecuronium is combined with Acetylglycinamide chloral hydrate.
Aclidinium
Vecuronium may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
Acotiamide
Acotiamide may decrease the neuromuscular blocking activities of Vecuronium.
Adinazolam
The risk or severity of adverse effects can be increased when Adinazolam is combined with Vecuronium.
Adipiplon
The risk or severity of adverse effects can be increased when Vecuronium is combined with Adipiplon.
Agmatine
Agmatine may increase the neuromuscular blocking activities of Vecuronium.
Agomelatine
The risk or severity of adverse effects can be increased when Vecuronium is combined with Agomelatine.